Cargando…
Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR
BACKGROUND AND OBJECTIVE: Schizophrenia is a low-prevalence mental disorder with a global age-standardized prevalence of 21 million people (2016). Second-generation antipsychotics (lurasidone and quetiapine XR) are recommended as the first-line treatment for schizophrenia. It is interesting to inves...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452921/ https://www.ncbi.nlm.nih.gov/pubmed/32648201 http://dx.doi.org/10.1007/s40261-020-00944-0 |
_version_ | 1783575257531023360 |
---|---|
author | Restelli, Umberto García-Goñi, Manuel Lew-Starowicz, Michal Mierzejewski, Pawel Silvola, Sofia Mayoral-van Son, Jacqueline Croce, Davide Rocca, Paola Crespo-Facorro, Benedicto |
author_facet | Restelli, Umberto García-Goñi, Manuel Lew-Starowicz, Michal Mierzejewski, Pawel Silvola, Sofia Mayoral-van Son, Jacqueline Croce, Davide Rocca, Paola Crespo-Facorro, Benedicto |
author_sort | Restelli, Umberto |
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: Schizophrenia is a low-prevalence mental disorder with a global age-standardized prevalence of 21 million people (2016). Second-generation antipsychotics (lurasidone and quetiapine XR) are recommended as the first-line treatment for schizophrenia. It is interesting to investigate how the results of clinical studies translate into direct medical costs. The objective of this analysis was to assess the direct medical costs related to pharmaceutical treatments and the management of relapses in patients affected with schizophrenia treated with lurasidone (74 mg) vs quetiapine XR (300 mg) assuming the Italian and Spanish National Health Service perspective. METHODS: A health economic model was developed based on a previously published model. The analysis considered direct medical costs related to the pharmacological therapies and inpatient or outpatient management of relapses (direct medical costs referred to 2019). The probability of relapses and related costs were derived from two systematic reviews. A deterministic sensitivity analysis was implemented to test the robustness of the results. RESULTS: The use of lurasidone (74 mg) compared with quetiapine XR (300 mg) would lead to a reduction in direct medical costs in Italy and Spain, with a lower cost per patient of − 163.7 € (− 9.0%) and − 327.2 € (− 22.7%), respectively. In detail, it would lead to an increase in the cost of therapy of + 53.8% and of + 30.5% in Italy and Spain, respectively, to a decrease in the cost of relapses with hospitalization of − 135.7%, and to an increase in the cost of relapses without hospitalization of + 24.5%. CONCLUSIONS: The use of lurasidone (74 mg) for the treatment of patients affected with schizophrenia, compared with quetiapine XR (300 mg), would be a cost-saving strategy in the two contexts investigated assuming the National Health Service point of view. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40261-020-00944-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7452921 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-74529212020-09-02 Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR Restelli, Umberto García-Goñi, Manuel Lew-Starowicz, Michal Mierzejewski, Pawel Silvola, Sofia Mayoral-van Son, Jacqueline Croce, Davide Rocca, Paola Crespo-Facorro, Benedicto Clin Drug Investig Original Research Article BACKGROUND AND OBJECTIVE: Schizophrenia is a low-prevalence mental disorder with a global age-standardized prevalence of 21 million people (2016). Second-generation antipsychotics (lurasidone and quetiapine XR) are recommended as the first-line treatment for schizophrenia. It is interesting to investigate how the results of clinical studies translate into direct medical costs. The objective of this analysis was to assess the direct medical costs related to pharmaceutical treatments and the management of relapses in patients affected with schizophrenia treated with lurasidone (74 mg) vs quetiapine XR (300 mg) assuming the Italian and Spanish National Health Service perspective. METHODS: A health economic model was developed based on a previously published model. The analysis considered direct medical costs related to the pharmacological therapies and inpatient or outpatient management of relapses (direct medical costs referred to 2019). The probability of relapses and related costs were derived from two systematic reviews. A deterministic sensitivity analysis was implemented to test the robustness of the results. RESULTS: The use of lurasidone (74 mg) compared with quetiapine XR (300 mg) would lead to a reduction in direct medical costs in Italy and Spain, with a lower cost per patient of − 163.7 € (− 9.0%) and − 327.2 € (− 22.7%), respectively. In detail, it would lead to an increase in the cost of therapy of + 53.8% and of + 30.5% in Italy and Spain, respectively, to a decrease in the cost of relapses with hospitalization of − 135.7%, and to an increase in the cost of relapses without hospitalization of + 24.5%. CONCLUSIONS: The use of lurasidone (74 mg) for the treatment of patients affected with schizophrenia, compared with quetiapine XR (300 mg), would be a cost-saving strategy in the two contexts investigated assuming the National Health Service point of view. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40261-020-00944-0) contains supplementary material, which is available to authorized users. Springer International Publishing 2020-07-09 2020 /pmc/articles/PMC7452921/ /pubmed/32648201 http://dx.doi.org/10.1007/s40261-020-00944-0 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Original Research Article Restelli, Umberto García-Goñi, Manuel Lew-Starowicz, Michal Mierzejewski, Pawel Silvola, Sofia Mayoral-van Son, Jacqueline Croce, Davide Rocca, Paola Crespo-Facorro, Benedicto Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR |
title | Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR |
title_full | Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR |
title_fullStr | Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR |
title_full_unstemmed | Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR |
title_short | Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR |
title_sort | cost of relapse management in patients with schizophrenia in italy and spain: comparison between lurasidone and quetiapine xr |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452921/ https://www.ncbi.nlm.nih.gov/pubmed/32648201 http://dx.doi.org/10.1007/s40261-020-00944-0 |
work_keys_str_mv | AT restelliumberto costofrelapsemanagementinpatientswithschizophreniainitalyandspaincomparisonbetweenlurasidoneandquetiapinexr AT garciagonimanuel costofrelapsemanagementinpatientswithschizophreniainitalyandspaincomparisonbetweenlurasidoneandquetiapinexr AT lewstarowiczmichal costofrelapsemanagementinpatientswithschizophreniainitalyandspaincomparisonbetweenlurasidoneandquetiapinexr AT mierzejewskipawel costofrelapsemanagementinpatientswithschizophreniainitalyandspaincomparisonbetweenlurasidoneandquetiapinexr AT silvolasofia costofrelapsemanagementinpatientswithschizophreniainitalyandspaincomparisonbetweenlurasidoneandquetiapinexr AT mayoralvansonjacqueline costofrelapsemanagementinpatientswithschizophreniainitalyandspaincomparisonbetweenlurasidoneandquetiapinexr AT crocedavide costofrelapsemanagementinpatientswithschizophreniainitalyandspaincomparisonbetweenlurasidoneandquetiapinexr AT roccapaola costofrelapsemanagementinpatientswithschizophreniainitalyandspaincomparisonbetweenlurasidoneandquetiapinexr AT crespofacorrobenedicto costofrelapsemanagementinpatientswithschizophreniainitalyandspaincomparisonbetweenlurasidoneandquetiapinexr |